This webcast on new and emerging treatments for newly diagnosed and R/R CLL/SLL with a focus on targeted inhibitors, presented by Dr. Susan O'Brien is intended for medical professionals and uses moderate "Med-Speak."
So only recommended for those accustomed to the medical language. But if you can follow it, it has lots of excellent detailed comparisons
-
Len
-
hmpeducation.com/content/ac...
hmpeducation.com/content/do...
This accredited, on-demand activity features a presentation that discusses the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with Bruton tyrosine kinase (BTK) inhibitors.
Learning Objectives
After participating in this activity, learners should be better able to:
• Assess the current treatment options for CLL beyond the current chemoimmunotherapy (CIT) standard
• Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with bruton tyrosine kinase (BTK) inhibitors
• Incorporate guideline recommendations for cytogenetic analysis and minimal residual disease (MRD) monitoring into the care of patients with CLL/SLL